



C-BRAIN

The Consortium for
Biomedical Research &
AI in Neurodegeneration

**A pioneering initiative
in AI-driven discovery**

Revolutionize

data analysis by applying
human-augmented AI

Accelerate

impactful discoveries
through collaboration

Deliver

an open-source model
to benefit the scientific
community and enhance
patient outcomes

The future of biomedical science
demands innovation, collaboration,
and the courage to rethink how
discoveries are made.

The Consortium for
Biomedical Research & AI in
Neurodegeneration (**C-BRAIN**)
is a world-wide, multi-sector
initiative aimed at transforming
biomedical research, leveraging
AI-driven discoveries to
accelerate breakthroughs in
treating Alzheimer's and other
neurodegenerative diseases.

A worldwide consortium forging the ideal data-driven scientific assistant

Advanced
Artificial Intelligence

Unprecedented
volumes of data

World-class experts
curate & train the AI



C-BRAIN will develop an “AI Biomedical Research Scientist” to assist human researchers by synthesizing data, generating hypotheses, and designing experiments. We aim to transform biomedical research by integrating across the discovery lifecycle.

Powered by collaboration among nearly 60 organizations worldwide:

- Led by researchers from academia, industry, and philanthropy, including WashU Medicine
- Tech industry giants
- Leading biopharma and biotech companies
- Philanthropic and non-profit organizations
- Government agencies

Visit c-brain.org to see listings of consortium members as they are announced.

Scalable: An initial focus on Alzheimer’s will expand to other neurodegenerative diseases

Human Collaboration: Designed to work alongside researchers, bridging the gap between data and discovery

Expertise: Academic/industry collaboration to ensure AI tools meet scientific needs

AI Training: Reading scientific literature, integrating complex datasets, generating new hypotheses, and designing experiments

Breadth and depth of data, including proprietary and unpublished datasets from industry — all within a secure, ethical, and coordinated framework

Focus: Targeted at biomedical research, not clinical applications or drug discovery

Urgent challenge, opportune moment

Neurodegenerative diseases like Alzheimer’s are difficult to treat, with a high failure rate for drug candidates due to a fragmented research ecosystem. The advent of AI, combined with large data sets and scientific expertise, can overcome these challenges, speed discovery, and improve patient outcomes.

Join us in building a collaborative AI-driven framework to revolutionize biomedical research, accelerate breakthroughs and deliver hope to millions of affected patients worldwide.



Visit c-brain.org to learn more and register for updates.